6855 studies found for:    vaccine
Show Display Options
Rank Status Study
21 Completed
Has Results
Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year Old Healthy Children Who Previously Participated in Study V72P12E1
Conditions: Meningococcal Disease;   Meningococcal Meningitis
Interventions: Biological: 1 dose of Meningococcal (group B) multicomponent recombinant adsorbed vaccine;   Biological: 2 doses of Meningococcal (group B) multicomponent recombinant adsorbed vaccine
22 Completed
Has Results
Safety and Immunogenicity of a Group B Streptococcus Vaccine in Non Pregnant and Pregnant Women 18-40 Years of Age
Condition: Streptococcal Infections
Interventions: Biological: Group B Streptococcus Trivalent Vaccine - 20/20/20 μg;   Other: Saline solution;   Biological: Group B Streptococcus Trivalent Vaccine - 0.5/0.5/0.5 μg;   Biological: Group B Streptococcus Trivalent Vaccine - 2.5/2.5/2.5 μg;   Biological: Group B Streptococcus Trivalent Vaccine - 5/5/5 μg;   Other: saline solution
23 Unknown  Conjugate And Polysaccharide Vaccines Compared With Polysaccharide Vaccine In Hiv-Infected Adults
Conditions: Pneumococcal Vaccines;   HIV;   HIV Infections
Intervention: Biological: Prevenar and Pneumo23
24 Completed
Has Results
Safety and Dose Ranging Study of Acellular Pertussis and Acellular Pertussis -Tetanus-Diphtheria Booster Vaccines in Healthy Adults Ages 18 to 40 Years
Conditions: Pertussis;   Whooping Cough;   Tetanus;   Lockjaw;   Diphtheria
Interventions: Biological: Acellular pertussis vaccine;   Biological: Tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed);   Biological: Licensed TdaP booster vaccine;   Biological: Diphtheria and tetanus vaccine (adsorbed, reduced antigen content, Germany);   Other: Saline solution
25 Completed Study of Yellow Fever Vaccine Administered With Tetravalent Dengue Vaccine in Healthy Toddlers
Conditions: Dengue;   Dengue Hemorrhagic Fever;   Yellow Fever
Interventions: Biological: Live, attenuated dengue serotype 1, 2, 3, and 4 virus;   Biological: Yellow fever vaccine;   Biological: Measles, mumps, and rubella vaccine;   Biological: Pneumococcal Conjugated Vaccine;   Biological: Hepatitis A Pediatric Vaccine;   Biological: Diphtheria, tetanus, pertussis, polio, and Haemophilus influenzae vaccine;   Biological: Yellow Fever Vaccine;   Biological: Placebo (NaCl)
26 Recruiting Safety Study Of Chemotherapy Combined With Dendritic Cell Vaccine to Treat Breast Cancer
Condition: Breast Cancer
Interventions: Biological: LA TNBC: DC vaccine+Preop chemo;   Biological: ER+/HER2-BC:DC vaccine+Preop chemo
27 Completed
Has Results
Study of the Safety and Immune Response of a Meningococcal Vaccine Administered to Healthy Infants
Condition: Prevention of Meningococcal Disease
Interventions: Biological: MenACWY Ad- (MenACWY-CRM, non adjuvanted formulation);   Biological: MenACWY Ad+ (MenACWY-CRM, adjuvanted formulation);   Biological: MenACWY PS (MenACWY-CRM, polysaccharide vaccine);   Biological: HBV (Hepatitis B vaccine);   Biological: Prevnar (pneumococcal polysaccharide serotypes 4, 9V, 14, 18C, 19F, 23F & 6B conjugated to the CRM197);   Biological: MMR (Measles, Mumps and Rubella vaccine);   Biological: DTaPHibIPV (Diphtheria, Tetanus, acellular Pertussis, H. Influenzae type b, Inactivated Poliovaccine);   Biological: Menjugate (Men C conjugated vaccine)
28 Completed Pneumococcal Vaccine Booster Study in Healthy Children 12-18 Mths Old Previously Primed With the Same Vaccines
Conditions: Pneumococcal Disease;   Streptococcus Pneumoniae Vaccines
Interventions: Biological: Pneumococcal conjugate vaccine GSK1024850A;   Biological: Tritanrix-HepB;   Biological: Hiberix Hib vaccine;   Biological: Polio Sabin;   Biological: Poliorix;   Biological: Prevenar (Wyeth)
29 Completed
Has Results
Safety of a Influenza Vaccine Produced Either in Mammalian Cell Culture or in Embryonated Hen Eggs in Adults and Elderly With and Without Underlying Medical Conditions, and Immunogenicity in a Subset of Subjects With Underlying Medical Conditions
Conditions: Seasonal Influenza;   Vaccine
Interventions: Biological: Cell-derived influenza vaccine;   Biological: Egg-derived influenza vaccine
30 Completed Seasonal Influenza DNA Vaccine & Seasonal Influenza Trivalent Inactivated Vaccine (TIV) in Children & Adolescents
Condition: Influenza
Interventions: Biological: Seasonal Influenza DNA vaccine;   Biological: TIV
31 Completed
Has Results
Safety, Tolerability and Immunogenicity of Two Doses of Adjuvanted Monovalent Influenza Vaccine Administered to Healthy Adult and Elderly Subjects
Condition: Pandemic Influenza Disease
Interventions: Biological: Placebo;   Biological: Trivalent influenza virus vaccine (TIV);   Biological: Adjuvanted monovalent influenza virus vaccine (aH5N1);   Biological: Adjuvanted trivalent influenza vaccine (aTIV)
32 Completed Safety of an Inactivated Enterovirus Type 71 Vaccines in Healthy Children
Conditions: Hand-foot-mouth Disease;   Infection; Viral, Enterovirus
Interventions: Biological: 100U inactivated Enterovirus Type 71 Vaccine;   Biological: 200U inactivated Enterovirus Type 71 Vaccine;   Biological: 400U inactivated Enterovirus Type 71 Vaccine;   Biological: Placebo
33 Completed
Has Results
Safety and Immunogenicity of Different Meningitis Vaccine Formulations in Adolescents and Young Adults
Condition: Invasive Meningococcal Disease
Interventions: Biological: Meningococcal (groups A, C, W, Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine + OMV.;   Biological: Meningococcal (group B) multicomponent recombinant adsorbed vaccine plus OMV.;   Biological: Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine.;   Biological: Meningococcal (groups A, C, W, Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine + qOMV.
34 Completed
Has Results
Evaluation of Persistence of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received MenACWY Conjugate Vaccine
Condition: Meningococcal Meningitis
Interventions: Biological: MenACWY-CRM conjugate vaccine;   Biological: Licensed comparator
35 Completed Study of a Booster Injection of Pentaxim™ Vaccine Administered With Dengue Vaccine in Healthy Toddlers
Conditions: Dengue;   Dengue Hemorrhagic Fever
Interventions: Biological: Live, attenuated, recombinant dengue serotype 1, 2, 3, and 4 virus;   Biological: DTaP IPV//Hib vaccine;   Biological: Placebo;   Biological: Measles, mumps, and rubella vaccine;   Biological: Pneumococcal vaccine
36 Completed Evaluating the Safety and Immune Response to Two Admixtures of a Tetravalent Dengue Virus Vaccine
Condition: Dengue
Interventions: Biological: TetraVax-DV Vaccine - Admixture TV003;   Biological: TetraVax-DV Vaccine - Admixture TV005;   Biological: Placebo
37 Completed
Has Results
Sanofi H1N1 Influenza Vaccine Administered at Different Dose Levels With and Without AS03 Adjuvant in Healthy Adult and Elderly Populations
Condition: Influenza
Interventions: Drug: AS03;   Biological: Influenza Virus Vaccine, Monovalent A/H1N1 A/California/7/2009 NYMC X-179A
38 Completed Immunogenicity and Safety of Meningococcal (A, C, Y and W135) Conjugate Vaccine
Condition: Meningitis
Interventions: Biological: MCV-ACYW135 Vaccine Group;   Biological: MPV-ACYW135 Vaccine Group;   Biological: MPV-A Vaccine Group;   Biological: MCV-AC Vaccine Group;   Biological: Hib Vaccine Group
39 Completed Study of the Purified Vero Rabies Vaccine - Serum Free in Comparison With the Reference Purified Vero Rabies Vaccine
Conditions: Rabies;   Rabies Virus
Interventions: Biological: Purified inactivated rabies vaccine, serum free;   Biological: Purified Vero Rabies Vaccine
40 Completed
Has Results
A Phase 3B, Open Label, Multi-Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered Alone to Healthy Infants According to Different Immunization Schedules and to Healthy Children Aged 2 to 10 Years
Conditions: Meningococcal Disease;   Meningococcal Meningitis
Interventions: Biological: rMenB + OMV NZ vaccine;   Biological: Meningococcal C oligosaccharide conjugated vaccine;   Biological: Pneumococcal polysaccharide conjugate vaccine, 10 valent adsorbed.

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years